STAT

DECEMBER 17, 2023

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021. Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive.

325

325

Med Ed 101

DECEMBER 17, 2023

Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls related to semaglutide overdose — an increase of over 1500% since 2019 according to a […] The post Semaglutide Overdose – What Does It Look Like and Why Is It Happening?

Diabetes 105

Diabetes 105

STAT

DECEMBER 17, 2023

Every year, the health care industry behaves more and more like a balloon: Squeeze one side, and the other expands. Companies that were once just insurers or just pharmacies are tacking on new business lines. The idea is that when profit inevitably gets squeezed in one, it’ll expand in another. That trend of vertical integration was on full display in 2023, a year when the country’s biggest pharmacy chain bought a primary care provider, and the biggest private insurer branched furt

Hospitals 301

Hospitals 301

The Guardian - Pharmaceutical Industry

DECEMBER 17, 2023

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January A “gamechanging” drug that prevents hot flushes and could benefit hundreds of thousands of women has been approved for use in the UK. The green light for Veoza, also known as fezolinetant, comes after the US regulator, the Food and Drug Administration, authorised it for use in America in May.

109

109

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

pharmaphorum

DECEMBER 17, 2023

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.

103

103

The Guardian - Pharmaceutical Industry

DECEMBER 17, 2023

Health bosses condemn ‘irresponsible’ targeting of people desperate for NHS help Wellness firms are exploiting a national shortage of ADHD medication to push so-called “smart supplements” as an alternative to prescribed drugs. As patients struggle to get hold of medication – or face years-long waits for NHS assessments – companies are peddling unproved products as a “natural” treatment for attention deficit hyperactivity disorder.

92

92

Pharmacy Joe

DECEMBER 17, 2023

In this episode, I’ll discuss the bioavailability of methadone. Episode 879: What is the conversion of oral methadone to IV? Subscribe on iTunes , Android , or Stitcher Popular tertiary references suggest a conversion ratio of oral to IV methadone of 2:1, meaning 10 mg of oral methadone is equivalent to 5 mg of IV methadone. But a team of researchers recently published a scoping review on the bioavailability of methadone in the American Journal of Health-System Pharmacy that draws a different co

Inpatient 52

Inpatient 52

Drug Patent Watch

DECEMBER 17, 2023

Dasatinib is the generic ingredient in two branded drugs marketed by Apotex and Bristol Myers Squibb and is included in three NDAs. There are two patents protecting this compound. Drug… The post New tentative approval for Teva Pharms drug dasatinib appeared first on DrugPatentWatch - Make Better Decisions.

Compounding 59

Compounding 59

RX Note

DECEMBER 17, 2023

Introduction In an overview, Sale of Drugs Act 1952 and Control of Drugs and Cosmetics Regulations 1984 are legislations mainly discussing power and duties of few parties and manufacture of registered products or notified cosmetics. SODA - Sale of Drugs Act 1952 CDCR - Control of Drugs and Cosmetics Regulations 1984 DCA - Drug Control Authority Key Definitions "Drug" includes any substance, product or article intended to be used or capable, or purported or claimed to be capable, of being used on

Documentation 40

Documentation Labelling 40

Drug Patent Watch

DECEMBER 17, 2023

Icosapent ethyl is the generic ingredient in two branded drugs marketed by Apotex, Dr Reddys, Hikma, Strides Pharma, Teva Pharms Usa, Zydus, and Amarin Pharms and, and is included in… The post New tentative approval for Ascent Pharms drug icosapent ethyl appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. However, the Court refused to issue an injunction removing the infringing product from the Canadian market, finding that it was not in the public interest to force patients to switch to another biosimilar product.

Biosimilars 52

Biosimilars Dosage 52

Drug Patent Watch

DECEMBER 17, 2023

VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,832,351 Expiration: Dec 19, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 17, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

59

59